Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 2% increase in Q3 revenues to $21.1 billion, beating the Wall Street consensus. Earnings of $2.20 per share were also stronger than what analysts had anticipated.
JNJ shares were down 1.6% immediately following the announcement. The stock has gained 4% since the beginning of this year.
“Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” CEO Alex Gorsky said in a statement.
Prior performance
4Q19 
3Q19
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
